Pathophysiological idiosyncrasies and pharmacokinetic realities may interfere with tacrolimus dose titration in liver transplantation

European Journal of Clinical Pharmacology

Volumn 67, Issue 7, 2011, Pages 671-679

  Oteo, Itziar ^a   Lukas, John C ^a,b   Leal, Nerea ^b   Suarez, Elena ^a   Valdivieso, Andres ^a,c   Gastaca, Mikel ^c   De Urbina, Jorge Ortiz ^c   Calvo, Rosario ^a  

^a UNIVERSITY OF THE BASQUE COUNTRY UPV EHU   (Spain)

^b Dynakin SL   (Spain)

^c HOSPITAL DE CRUCES   (Spain)

Author keywords

Idiosyncrasy; Liver transplantation; Monitoring; Pharmacokinetic assumptions; Tacrolimus

Indexed keywords

ALBUMIN; ASPARTATE AMINOTRANSFERASE; AZATHIOPRINE; PREDNISONE; TACROLIMUS;

ADULT; ALBUMIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE TITRATION; DRUG MONITORING; EVENING DOSAGE; HEMATOCRIT; HUMAN; LIVER GRAFT REJECTION; LIVER TRANSPLANTATION; MAJOR CLINICAL STUDY; MORNING DOSAGE; POSTOPERATIVE PERIOD; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; STEADY STATE;

ADULT; AREA UNDER CURVE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER FUNCTION TESTS; LIVER TRANSPLANTATION; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; TACROLIMUS;

EID: 79959701335     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-011-0998-3     Document Type: Article

References (27)

1. Wallemacq P, Armstrong VW, Brunet M, Haufroid V, Holt DW, Johnston A et al (2009) Opportunities to optimize tacrolimus therapy in solid organ transplantation: report of the European consensus conference. Ther Drug Monit 31:139-152
2. Antignac M, Hulot JS, Boleslawski E, Hannoun L, Touitou Y, Farinotti R et al (2005) Population pharmacokinetics of tacrolimus in full liver transplant patients: modelling of the post-operative clearance. Eur J Clin Pharmacol 61:409-416 (Pubitemid 41569318)
3. Fukudo M, Yano I, Masuda S, Goto M, Uesugi M, Katsura T et al (2006) Population pharmacokinetic and pharmacogenomic analysis of tacrolimus in pediatric living-donor liver transplant recipients. Clin Pharmacol Ther 80:331-345 (Pubitemid 44479749)
4. Lee JY, Hahn HJ, Son IJ, Suh KS, Yi NJ, Oh JM et al (2006) Factors affecting the apparent clearance of tacrolimus in Korean adult liver transplant recipients. Pharmacotherapy 26:1069-1077 (Pubitemid 44167815)
5. Zahir H, McCaughan G, Gleeson MN, McLachlan RA (2003) Factors affecting variability in distribution of tacrolimus in liver transplant recipients. Br J Pharmacol 57:298-309
6. Christians U, Jacobsen W, Benet LZ, Lampen A (2002) Mechanisms of clinically relevant drug interactions associated with tacrolimus. Clin Pharmacokinet 41:813-851
7. Staatz CE, Tett SE (2004) Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet 43:623-653 (Pubitemid 38981845)
8. Böttiger Y, Brattström C, Tydén G, Säwe J, Groth CG (1999) Tacrolimus whole blood concentrations correlate closely to side-effects in renal transplant recipients. Br J Clin Pharmacol 48:445-448 (Pubitemid 29417731)
9. Kuypers DR, Claes K, Evenepoel P, Maes B, CoosemansW, Pirenne J et al (2004) Time-related clinical determinants of long-term tacrolimus pharmacokinetics in combination therapy with mycophenolic acid and corticosteroids: a prospective study in one hundred de novo renal transplant recipients. Clin Pharmacokinet 43:741-762 (Pubitemid 39159005)
10. Karafoulidou A, Suarez E, Anastasopoulou I, Katsarou O, Kouramba A, Kotsi P et al (2009) Population pharmacokinetics of recombinant factor VIII:C (ReFacto® )) in adult HIV-negative and HIV-positive haemophilia patients. Eur J Clin Pharmacol 65:1121-1130
11. Fukudo M, Yano I, Shinsako K, Katsura T, Takada Y, Uemoto S et al (2009) Prospective evaluation of the Bayesian method for individualizing tacrolimus dose early after living-donor liver transplantation. J Clin Pharmacol 49:789-797
12. Jusko W, Piekoszewski KG, Shaefer M, Hebert M, Piergies A et al (1995) Pharmacokinetics of tacrolimus in liver transplant patients. Clin Pharmacol Ther 57:281-290
13. Sam WJ, Aw M, Quak SH, Lim SM, Charles BG, Chan SY et al (2000) Population pharmacokinetics of tacrolimus in Asian paediatric liver transplant patients. Br J Clin Pharmacol 50:531-541 (Pubitemid 32010014)
14. Macchi-Andanson M, Charpiat B, Jelliffe RW, Ducerf C, Fourcade N, Baulieux J (2001) Failure of traditional trough levels to predict tacrolimus concentrations. Ther Drug Monit 23:129-133 (Pubitemid 32240139)
15. Zahir H, McLachlan AJ, Nelson A, McCaughan G, Gleeson M, Akhlaghi F (2005) Population pharmacokinetic estimation of tacrolimus apparent clearance in adult liver transplant recipients. Ther Drug Monit 27:422-430 (Pubitemid 41098815)
16. Sam WJ, Tham LS, Holmes MJ, Marion AW, Quak SH, Lee KH et al (2006) Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients. Clin Pharmacokinet 45:59-75 (Pubitemid 43145015)
17. Blanchet B, Duvoux C, Costentin CE, Barrault C, Ghaleh B, Salvat A et al (2008) Pharmacokinetic- pharmacodynamic assessment of tacrolimus in liver-transplant recipients during the early post Tx period. Ther Drug Monit 30:412-418
18. Staatz CE, Willis C, Taylor PJ, Lynch SV, Tett SE (2003) Toward better outcomes with tacrolimus therapy: population pharmacokinetics and individualized dosage prediction in adult liver transplantation. Liver Transpl 9:130-137 (Pubitemid 36204563)
19. Kahan BD, Koch SM (2001) Current immunosuppressant regimens: considerations for critical care. Curr Opin Crit Care 7:242-250 (Pubitemid 32868474)
20. Venkataramanan R, Shaw LM, Sarkozi L, Mullins R, Pirsch J, MacFarlane G et al (2001) Clinical utility of monitoring tacrolimus blood concentrations in liver transplant patients. J Clin Pharamacol 41:542-551 (Pubitemid 32381872)
21. Undre NA, Schafer A (1998) Factors affecting the pharmacokinetics of tacrolimus in the first year after renal transplantation. European tacrolimus multicentre renal study group. Trans Proc 30:1261-1263 (Pubitemid 28309564)
22. Dansirikul C, Staatz CE, Duffull SB, Taylor PJ, Lynch SV, Tett SE (2006) Relationships of tacrolimus pharmacokinetic measures and adverse outcomes in stable adult liver transplant recipients. J Clin Pharm Ther 31:17-25
23. Holt DW, Johnston A (2004) Monitoring immunosuppressive drugs. Has it a future? Ther Drug Monit 26:244-247
24. Armendariz Y, Pou L, Cantarell C, Lopez R, Perello M, Capdevila L (2005) Evaluation of a limited sampling strategy to estimate area under the curve of tacrolimus in adult renal transplant patients. Ther Drug Monit 27:431-434 (Pubitemid 41098816)
25. Wavamunno MD, Chapman JR (2008) Individualization of immunosuppression: concepts and rationale. Curr Opin Organ Transpl 13:604-608
26. Minematsu T, Sugiyama E, Kusama M, Hori S, Yamada Y, Ohtani H et al (2004) Effect of hematocrit on pharmacokinetics of tacrolimus in adult living donor liver transplant recipients. Transplant Proc 36:1506-1511 (Pubitemid 38903017)
27. Staatz CE, Goodman LK, Tett SE (2010) Effect of CYP3A and ABCB1 Single nucleotide polymorphisms on the pharmacokinetics and pharmacodynamics of calcineurin inhibitors: Part II. Clin Pharmacokinet 49:207-221